25,667 Shares in Sotera Health (NASDAQ:SHC) Purchased by Empowered Funds LLC

Empowered Funds LLC purchased a new position in shares of Sotera Health (NASDAQ:SHC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,667 shares of the company's stock, valued at approximately $351,000.

Several other hedge funds also recently bought and sold shares of the stock. Pacer Advisors Inc. raised its position in shares of Sotera Health by 9.0% in the fourth quarter. Pacer Advisors Inc. now owns 34,773 shares of the company's stock valued at $476,000 after buying an additional 2,866 shares during the last quarter. KBC Group NV grew its stake in Sotera Health by 4,094.6% in the 4th quarter. KBC Group NV now owns 186,365 shares of the company's stock worth $2,549,000 after acquiring an additional 181,922 shares during the period. Blue Trust Inc. raised its holdings in Sotera Health by 164.3% in the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock valued at $25,000 after acquiring an additional 1,140 shares during the last quarter. First Citizens Bank & Trust Co. lifted its stake in shares of Sotera Health by 16.8% during the 4th quarter. First Citizens Bank & Trust Co. now owns 16,689 shares of the company's stock worth $228,000 after purchasing an additional 2,402 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Sotera Health by 271.6% during the fourth quarter. SG Americas Securities LLC now owns 36,364 shares of the company's stock worth $497,000 after purchasing an additional 26,577 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Barclays reduced their target price on Sotera Health from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. The Goldman Sachs Group assumed coverage on Sotera Health in a research report on Friday, December 6th. They set a "neutral" rating and a $14.00 price target for the company. Citigroup lifted their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $16.08.

Sotera Health Stock Performance

Shares of NASDAQ SHC traded up $0.09 during trading on Monday, reaching $13.61. The stock had a trading volume of 158,795 shares, compared to its average volume of 848,342. The firm's 50 day moving average price is $13.45 and its two-hundred day moving average price is $14.56. Sotera Health has a one year low of $10.71 and a one year high of $17.44. The stock has a market cap of $3.86 billion, a PE ratio of 54.43 and a beta of 1.91. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.